Nasdaq's determination is based on the Company meeting the continued listing requirement for market value of publicly held shares and all other applicable initial listing standards for The Nasdaq ...

This U.S.-based manufacturing agreement builds upon Oragenics’ broader strategy to develop scalable, accessible, and fast-acting treatments for neurological trauma, beginning with concussion, a ...

NeuroRush™ delivers a unique blend of adaptogens and nootropic herbs designed to enhance cognitive performance, stress response and long-term brain health, without dependency or burnout.

Lattimore’s move to Air represents a major milestone in its broader technology modernization strategy. By consolidating billing, charting, and ambient documentation into a single, AI-enabled system, ...

The successful recent installation and validation of this iHP isolator is the first completed deployment of the SIS-SA, part of the SteraMist Integrated Systems (SIS) launched in the second half of ...

Trading on split-adjusted basis will begin at market open on July 29, 2025. This adjustment is expected to help Silexion comply with NASDAQ requirements, enhance its market position, and support its ...

Forward-looking statements speak only as of the date they are made. Scienture Holdings, Inc. undertakes no obligation to update or revise any forward-looking statements, whether as a result of new ...

Kuala Lumpur, Malaysia, July 16, 2025 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; “Cyclacel” or the “Company”), a biopharmaceutical company developing innovative ...

Andrew J. Oakley, Chairman of the Board of Onconetix, stated, “We continue to believe that the proposed transaction with Ocuvex, which brings a pipeline of commercial and late clinical stage ...

Fat Loss and Body Recomposition: SARMs aid in fat burning by increasing metabolic rate and preserving lean muscle during fat ...

Just Like Family Home Care, a trusted Canadian company, is proud to announce the launch of its services in Newmarket, Aurora, ...

Under the agreement, Amphista is responsible for the discovery and early development of small molecule protein degraders using its Eclipsys® platform. Merck is granted a global exclusive license to ...